Saturday – Plenary Session 3 Survey

Name Badge ID(Required)

Full Name(Required)

Enter your first and last names as you would like them to appear on your certificates.

First Last

Email(Required)

Enter the email you used to register for TOXINS 2022.

Please evaluate the speakers

Overall Evaluation

Topic and Speaker(s)

	Excellent	Good	Fair	Poor
Welcome Back David Simpson, MD (USA)
Questions about BoNT you were afraid to ask David Simpson, MD (USA) Giampietro Schiavo, PhD (UK) Nowell Solish, MD (Canada) Katharine Alter, MD (USA) Francisco Cardoso, MD (Brazil) Ornella Rossetto, PhD (Italy)
Best Clinical Abstract
Best Basic Science Abstract
Advances in urology: Indications, outcomes and new modes of BoNT delivery Roger Dmochowski, MD (USA)
Long-acting botulinum toxin Peter McAllister, MD (USA)
BoNT sero- and sub-type–specific neuronal selectivity Andreas Rummel, PhD (Germany)
Closing Remarks Katharine Alter, MD (USA)

Presentation free of commercial bias?

	Yes	No
Welcome Back David Simpson, MD (USA)
Questions about BoNT you were afraid to ask David Simpson, MD (USA) Giampietro Schiavo, PhD (UK) Nowell Solish, MD (Canada) Katharine Alter, MD (USA) Francisco Cardoso, MD (Brazil) Ornella Rossetto, PhD (Italy)
Best Clinical Abstract
Best Basic Science Abstract
Advances in urology: Indications, outcomes and new modes of BoNT delivery Roger Dmochowski, MD (USA)
Long-acting botulinum toxin Peter McAllister, MD (USA)
BoNT sero- and sub-type–specific neuronal selectivity Andreas Rummel, PhD (Germany)
Closing Remarks Katharine Alter, MD (USA)

If you answered “No, this presentation was not free of commercial bias”, on any of the above, please explain your reason(s).

Applicable to my practice/research

	Yes	No
Welcome Back David Simpson, MD (USA)
Questions about BoNT you were afraid to ask David Simpson, MD (USA) Giampietro Schiavo, PhD (UK) Nowell Solish, MD (Canada) Katharine Alter, MD (USA) Francisco Cardoso, MD (Brazil) Ornella Rossetto, PhD (Italy)
Best Clinical Abstract
Best Basic Science Abstract
Advances in urology: Indications, outcomes and new modes of BoNT delivery Roger Dmochowski, MD (USA)
Long-acting botulinum toxin Peter McAllister, MD (USA)
BoNT sero- and sub-type–specific neuronal selectivity Andreas Rummel, PhD (Germany)
Closing Remarks Katharine Alter, MD (USA)

This activity should improve my

	Strongly disagree	Disagree	Neutral	Agree	Strongly agree
Ability to evaluate the latest clinical and scientific research into botulinum neurotoxins
Understanding of the clinical utility of botulinum neurotoxins
Understanding of potential new therapeutic applications of botulinum neurotoxins
Biomedical knowledge of botulinum and other neurotoxins and their application in enhancing therapeutics and improving care

Comments